CA2231714A1 - Additive preparation and method of use thereof - Google Patents
Additive preparation and method of use thereof Download PDFInfo
- Publication number
- CA2231714A1 CA2231714A1 CA002231714A CA2231714A CA2231714A1 CA 2231714 A1 CA2231714 A1 CA 2231714A1 CA 002231714 A CA002231714 A CA 002231714A CA 2231714 A CA2231714 A CA 2231714A CA 2231714 A1 CA2231714 A1 CA 2231714A1
- Authority
- CA
- Canada
- Prior art keywords
- additive preparation
- acid
- additive
- weight percent
- carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/25—Reference solutions for assays of biological material containing added polymers to stabilise biological material against degradation or mantain viscosity or density, e.g. gelatin, polyacrylamides, polyvinyl alcohol
- G01N2496/35—Polyvinylpyrrolidone, e.g. PVP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Abstract
The present invention is an additive preparation which comprises an additive, an organic acid and a metal carbonate compound. The preparation effervesces when in contact with a body fluid sample, thereby efficiently dispersing in a body fluid sample.
Description
CA 02231714 1998-03-0~
METHOD C)F USE THEREOF
1~
BACKGROUND~ OF THE INVENTION
1. FIELD C)F THE INVENTION
l'j The present invention is an additive preparation for use in collection devices wherein the additive preparation effervesces when in contact with a body fluid. The additive preparation desirably comprises a formulation comprising an additive such as a clot activator, anticoagulant or urine preservation material, an organic acid and a metal carbonate compound. The effervescence e:Efect of the formula-tion aids in dispersal and delivery of the additive in a blody fluid sample. The formulation is desirably tableted to provide an effective, easily stored and handled preparation. In particular, the formulation of the present invention preferably comprises a clot activator or 2'j anticoagulant, an organic acid and a metal carbonate compound wherein the formulation en:hances clot activation or the anticoagulant effect in a blood speclmen.
2. DESCRIPTION OF RELATED ART
METHOD C)F USE THEREOF
1~
BACKGROUND~ OF THE INVENTION
1. FIELD C)F THE INVENTION
l'j The present invention is an additive preparation for use in collection devices wherein the additive preparation effervesces when in contact with a body fluid. The additive preparation desirably comprises a formulation comprising an additive such as a clot activator, anticoagulant or urine preservation material, an organic acid and a metal carbonate compound. The effervescence e:Efect of the formula-tion aids in dispersal and delivery of the additive in a blody fluid sample. The formulation is desirably tableted to provide an effective, easily stored and handled preparation. In particular, the formulation of the present invention preferably comprises a clot activator or 2'j anticoagulant, an organic acid and a metal carbonate compound wherein the formulation en:hances clot activation or the anticoagulant effect in a blood speclmen.
2. DESCRIPTION OF RELATED ART
3() Blood collected in evacuated tubes often must be clotted prior to clinical examin~tion because it is desirab~le to form a dense clot as rapidly and completely as possible to facilitate clean separation of the clot from the serumlayer by centri:~ugation. To achiel~e this end, both plastic and glass blood 3'j collection tubes frequently employ a clot activator. Typical clot activators are diatomaceous earth and particles of inorganic silicates, or biochemicals such CA 0223l7l4 l998-03-0~
as ellagic acid, -thrombin, trypsin and thromboplastin.
Typical clot activators used commercially are silica coated on fabric, silica particles in small plastic cups or silicate particles applied to the tubewall with a polyvinylpyrrolidone (PVP) carrier. However, in these type of arrangements, it is necessary for the user to initiate mixing of the sample so that the activator is bioavailabile to the specimen thus providing the desired effect of the aclditive in the sampLe. Therefore, the mixing requirement is critical to obtaining the desired effect of the additives.
Maximum effectiveness is ac:hieved by thorough dispersion of the clot activator throughout the blood sample. Since clot activator materials are generally in powder form or as a wall coating, mixing of the clot activator with the blood sample to achieve dispersion may be a physically awkward operation. Also complete dispersion of the clot activator material in the blood sample tends to be frustrated by the tendency of the clot activator material to agglomerate upon moistening.
In addition, agglomerated clot activator particles tend to settle relatively rapidly, according to Stokes Law, which provides that the settling rate of a particle in a dispensing fluid will be governed by its relative diameter and density as well as the fluid's viscosity and density.
Therefore, there is a need for providing a means for deploying an additive in a body fluid with minimal requirements of the user to initiate mixing of the additive and the body fluid and whereby the additive is able to provide rapid and reliable performance under variable handling conditions.
More particularly, there is a need for a blood collection tube with means for promoting c:lot-acceleration of a blood sample which provides an enhanced rate of blood coagulation (shortened time for blood coagulation) without leaving any substantial amount of soluble or particulate material in the serum layer on centrifugation, thus avoiding potential interference with CA 02231714 1998-03-0~
clinical tests, particularly in blood banking procedures. Whereas there are numerous commercial products available that employ clot activators, these products are unable to satisfactorily provide a shortened time for blood coagulation or provide a sample with minimal soluble or particulate material !, in the serum la'yer.
SUMMARY OF THE INVENTION
The present invention is an additive formulation for use in collection 10 devices wherein the additive preparation effervesces when in contact with a body fluid. The additive preparation desirably comprises a formulation comprising an aLdditive, an organic aLcid and a metal carbonate compound.
Desirably, the additive is a clot activator, anticoagulant, urine 1!~ preservation material or any other body fluid preservative.
In addition, the additive formulation may further comprise a stabilizer and/or a flow improver or a binder.
Desirably, the additive formulation comprises:
(a) from about 40 weight percent to about 90 weight percent of an additive;
(b) from about 5 weight percent to about 30 weight percent of an 2!~ organic acid or mixtures thereof; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate compound.
The present invention is most preferably an additive formulation for 30 enhancing clot activation of a b]Lood sample. The additive formulation CA 02231714 1998-03-0~
desirably comprises a clot activator, an organic acid and a metal carbonate compound.
Preferably, the clot activator additive formulation comprises:
, (a) from ;about 40 weight percent to' about 70 weight percent of a clot activa,tor;
(b) from about 10 weight percent; to about 26 weight percent of an organic acid or mixtures thereof; and o (c) from about 10 weight percent to about 26 weight percent of a metal carbonate.
The additive formulation ma,y further comprise a binding agent from about 6 weight percent to about 30 ~weight percent of a binder.
1 .~
The clot activator may be diatomaceous earth, particles of inorganic silicates or biochemicals such as ellagic acid, thrombin, trypsin and thromboplastin or combinations thereof.
21~ A significant attribute of t,he additive formulation of the present invention is its use in collection devices wherein the additive preparation effervesces when in contact with a body fluid sample. The effect of the additive preparation therefore aids in the dispersal and delivery of the additive to a body fluid sample.
A significant attribute of the clot activator additive formulation of the present invention is its use in blood collection devices as an effective and efficient means for promoting blood coagulation. Most importantly is that the additive formu],ation and the blood sample does not have to be mixed by the user.
CA 02231714 1998-03-0~
An import;ant advantage of the clot activator additive formulation of the present invention is its ease of use not requiring lengthy time to promote blood coagulation as compared to conventional techniques.
';
Notably, t,he formulations of t;he present invention rapidly disintegrate and disperse in a body fluid sample, thereby minimi7.ing the requirement that the user assist in mixing the formulation and the body flùid sample.
DESCRIPTION OF THE DRAWINGS
FIG. 1 is a perspective view of a typical blood collection tube with a stopper.
~, FIG. 2 is ;a longitudinal sectional view of the tube of FIG. 1 taken along line 2-2, comprising the additive formulation of the present invention.
DETAILED DESCRIPTION
The present invention may be embodied in other specific forms and is not limited to any specific embodim~ents described in detail which are merely exemplary. Various other modifical,ions will be apparent to and readily made by those skilled in the art without departing from the scope and spirit of the invention. The scope of the invention will be measured by the appended claims and their equivalents.
The addit,ive formulation of the present invention comprises:
(a) from about 40 weight percent to about 90 weight percent of a clot aCtiVcltOr;
(b) from about 5 weight percent to about 30 weight percent of an CA 02231714 1998-03-0~
organic acid; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate.
ci The additive formulation may further comprise a binding agent from about 5 weight percent to about 30 ~eight percent.
Desirably, the pH of the formulation is from about 5 to about 9, preferably from about 6 to about (3 and most preferably from about 6.5 to 10 about 7.5.
A clot activator material is preferably used in the formulation to initiate rapid c lotting of a blood sample that comes in contact with the formulation of the present invention.
1'~
A blood specimen often needs to be clotted to obtain serum. Serum is the specimen of choice for performing blood chemistries.
Desirably, the clot activator :materials, include, but are not limited to, 2l~ diatomaceous earth, inorganic silicates, ellagic acid, thrombin, trypsin and thromboplastin.
The preferred clot activator material for use in the formulation of the present invention is silica. A commercially available silica material is Min-U-Sil (trademark of Pennsylvania Glass Company, PA). Preferably, silica maybe present in the formulation such that the acceleration of the clotting mechanism is substantially achieved while minimi7.ing visual hemolysis or impacting chernistry analytes of the blood sample in an amount from about 40 to about 90 weight percent and most preferably at about 50 weight percent.
An organic acid is also preferably used in the formulation of the present CA 02231714 1998-03-0~
invention to initiate an effervescent reaction in the presence of water.
Desirably, the organic acid includes, but is not limited to, organic compounds containing at least one carboxylic acid functionality such as s tartaric acid, ci-tric acid, malic acid, maleic acid, fumaric acid, succinic acid, ascorbic acid and mixtures thereof.
The preferred organic acid for use in the formulation of the present invention is citric acid. Preferably, citric acid may be present in the o formulation in an amount from about 5 to about 30 weight percent and more preferably at about 25 weight percent.
A metal carbonate compound is also preferably used in the formulation of l;he present invention to initiate the disintegrating reaction in the presence 1!~ of acid and water.
Preferably, the metal carbonate compound is water soluble and includes, but is not limited to an alkali metal salt, sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate, cadmium carbonate, calcium carbonate, rubidium carbonate, potassium bicarbonate, soclium benzoate, sodium phosphate~ monobasic and sodium glycine carbonate.
Most pref-erably the metal carbonate compound is an alkali metal salt.
The preferred alkali metal salt for use in the formulation of the present invention is sodium bicarbonate. Preferably, sodium bicarbonate may be present in the formulation in an amount from about 5 to about 30 weight percent and more preferably at about 25 weight percent.
Most preferably the additive formulation of the present invention co m priSeS:
CA 02231714 1998-03-0~
(a) fronn about 50 weight percent of silica;
(b) fronn about 25 weight percent of citric acid; and (c) fronn about 25 weight percent of sodium bicarbonate.
';
An alternate embodiment of the present invention includes an additive formulation connprising:
(a) from aLbout 40 weight percent to about 90 weight percent of a clot activator;
(b) from about 5 weight percent to about 30 weight percent of an organic acid;
(c) from aLbout 5 weight percent to about 30 weight percent of a metal carbonate; and 1!~ (d) from about 5 weight percent to about 30 weight percent of a binding agent.
Most preferably the alternate embodiment of the present invention cornprlses:
21~
(a) frorn about 50 weight percent of a clot activator;
(b) frorn about 20 weight percent of an organic acid;
(c) from about 20 weight percent of a metal carbonate; and (d) from about 10 weight percent of a binder.
A binding or bulking agent may be used in the formulation of the present invention to provide binding and lubricating properties to the formulation.
Preferably the binding agent includes but is not limited to polyvinyl-py:rrolidone (PVP) polyvinyl-alcohol (PVA) polyethylene glycol (PEG) CA 02231714 1998-03-0~
carboxymethyl cellulose or corn starch.
The preferred binding agent for use in the formulation of the present invention is polyvinylpyrrolidone (E'VP). Preferably, PVP may be present in s the formulation in an amount from about 5 to about 30 weight percent.
A binding agent enables granulating of the formulation without the forming of a pellet.
o Polyvinylpyrrolidone is soluble in water and in a number of polar and non-polar organic solvents. Polyvinylpyrrolidone therefore serves as a binder and as a lubricant. Therefore, when the pellet of the present invention is dissolved in water, there is substantially no insoluble residue.
~, The polyvinylpyrrolidone used in the present invention is a polymer of vinylpyrrolidone having a molecular weight of about 1~,000 to about 200,000.
PVP is soluble in water and is also soluble in many organic solvents such as aliphatic alcohLols, chlorinated hydrocarbons, esters, nitroparaffins and am.lnes.
21~
Most prel-erably, the components of the formulation are in a physically bound form to maximize the dispersion of the formulation. They may be bound into pellets, pills, capsules, granules, tablets and the like may all be used in the practice of this invention. Most preferably, the formulation of the 2~ present invention is in pellet form. Pellet form is convenient because the formulation will rapidly disperse in the blood sample.
A dry compression techniqu.e may be used to form a pellet of the formulation of the present inventiom CA 0223l7l4 l998-03-0~ ' The dry oompression technique consists of mixing the components of the formulation and then applying sufficient force to form a pellet. The heat of compression binds the dry powder together, to form a pellet. The pellet formulation of l,he present invention is prepared by mixing the ingredients in a standard shaker for about two (2) hours or until a fine blend mixture is obt;ained. Then small portions of the mixed batch of powder are aliquoted into a manual puncher. The manual puncher consists of a piston-cylinder assembly. AlLiquoted powder is placed in the die cavity and force is applied by means of a hydraulic or pneumatic press. Typically, the aliquoting and pressing operal~ions are automatically performed in commercially available tablet presses.
Other ingredients which are conventional or desirable in various pellet formulations m.ay also be added to the formulation as long as they do not adversely affect; the overall properties of the formulation.
The addil,ive preparation of the present invention is preferably located in a collection clevice. The device is most preferably a blood collection deviceand may be eil,her an evacuated blood collection device or a non-evacuated blood collection device. The collection device is desirably made of plastic, such as but not limited to polyethylene terephthalate, or polypropylene or glass.
Referring to the drawings in which like reference characters refer to like parts throughout the several views thereof, FIG. 1 shows a typical blood collection device 10, having an open end 16, a closed end 18, inner wall 12, and a stopper 14 that includes a lower annular portion or skirt 15 which extends into and presses against the inner wall 12 of the tube for maintaining stopper 14 in p]Lace.
FIG. 2 shows device 10 with an additive preparation 20.
CA 0223l7l4 l998-03-0~
A blood specimen sample of interest can be transferred into device 10, wherein the specimen contacts the additive so that the additive rapidly disperses into t:he specimen and clot activation is initiated.
The following examples are not limited to any specific embodiment of the invention, blut are only exemplary.
PREPARATION OF ADDITIVE FORMULATION
The additive formulation of the present invention was prepared with the following ingredients as listed in Table 1:
Ingredients Weight Percent (%) Grams ~gm) silica 50 1.0 (Min-U-Sil, Pennsylvania Glass Compa:ny) baking soda 48 1.0 (Mixture of sodium bicarbonate and tartaric acid, Mfg: Arm and l~ammer) citric acid 2 0.0 (Sigma Chemicals Catalog No. C1909, Lot No.
~L~H0868) CA 0223l7l4 l998-03-0~
In a mixing vessel, all of the above ingredients were mixed together.
The mixture was then blended u sing a mortar and pestle for about 20 minutes or unt;il a fine blend was obtained. Twenty (20) pellets weighing !~ approximately 1.25 mg each were formed using a puncher. Because of the ma nual force applied on the puncher during the aliquoting process the powdered mate rial formed into a pellet.
1~
EFFECTI~IENESS EVAL,UATlON OF ADDITIVE FORMULATION
The effectiveness of the preparations of Example 1 were assessed by measuring the amount of silica available in the supernatant of added water.
1:5 In other words, the measurement oi-- silica not sedimented at the bottom of the tube whereby the silica in the su pernatant represents silica available for clotting in the blood.
The pellets prepared in Example 1 were added to twenty 16 x 100 mm plaLstic tubes. 'l'hese twenty tubes were separated into groups of ten, Group A
and Group B. Group C consisted of the control tubes~ twenty 13 x 100 mm plastic tubes with a wall coating c:onsisting of a mixture of silica, PVP and surfactant and a gel at the bottom. These tubes are VACUTAINER~' brand PL,US tubes.
The 16x100 mm tubes used in this experiment were marked for 8 ml fil~. There was also a second mark on these tubes, placed near the closed or bottom end of 1,he tube. The bottonn mark acted as an indicator for pipetting wa.ter from the tube, without disturbing the sedimented silica. This ensured that silica that is at the bottom oi- the tube is not aspirated along with the CA 02231714 1998-03-0~
supernatant, thus giving falsely elevated numbers for amount of silica in the solution.
These twenty tubes were further separated into groups of ten tubes each. The reason for the two separate groups was during the experiment one group was to be mixed while other one remained unmixed.
For controls, twenty 13xlO0 mm plastic tubes with wall coating consisting of a mixture of silica, PVP, and surfactant were used (VACUTAINE~'~ brand PLUS tubes, Lot # DG061096tI). These tubes also had gel at the bottom of the tube. These tubes were also separated into groups of 10 each.
De-ionized (DI) water was added to all the prototype and control tubes, one tube at a time. For the unmixed set of tubes, the DI water was immediately pipetted out. Nephelometry (Hach Turbiditimeter), which measures the amount of suspended particles, was done on these collected samples immediately. For the mixed tubes the methodology used was identical, except mixing with five inversions was done before pipetting the DI
water.
Table 2 llsts the amount of silica per mL of water in the supernatant.
The data clearly indicates that l;he pellets in both mixed and unmixed conditions outperformed the wall coated tubes.
SILICA IN SUPERNATANT
s (SAMPL]3 SIZE, N = 10) 'l'ube Type Handling Amt. of Silica Amt. of silica in (wt%) Condition dispensed the Supernatant (#of Inversions) (mg/mL) ~mg/mL) E'rototype 0 0.08 0.07 87.~
Control 0 0.15 0.05 33.33 Prototype ~ 0.08 0.1* 100 Control 6 0.15 0. 09 60 * Over recol)ery was attributed to the turbule~ce caused by m ixing and nephelometry reading the air bubbles irl mixing as silicaparticles.
11) PREPARATION OF ADDITIVE FORMULATION
, The addil,ive formulation of the present invention was prepared with the following ingredients as listed in Table 3:
TAlBLE 3 Imgredients Weight Percent s Llica 50 sodium bicarbonate 25 citric acid 25 CA 02231714 1998-03-0~
EXAMPI,E 4 CLINICAL EFFICACY OF THE PELLETS
r~ To demor-strate the clinical efficacy of the dispersion of the pellets in Example 3, a f:ive donor clinical study of human donors was performed and the clotting performance and select analytes of the samples were evaluated.
The measure of clotting performance was visual evaluation for gelation 10 of blood as well as presence of fibrin mass post centrifugation. The presence of fibrin mass after centrifugation demonstrates an incomplete clotting process even if the blood has completely gelled prior to centrifugation. In this experiment the prototype and control tubes were centrifuged for 10 minutes after waiting for 15 minutes post specimen collection 1~
Table 4 lists the visual observations done for clotting, while Table 5 lisl;s the results from the analyte measurements done on these tubes.
VISUAL OBSERVATIONS (SAMPLE SIZE N=5) Tube Type Number of Tubes not Fibrin Clotted before ~Iass Centrifugation Prototype 1 2 (Formulation per l~xamp]e 3)(13 X 100 mm plastic tube with first coat of surfactant, Pellet wt.=1.5 mg) Control- l 5 5 (Glass, 13xlOO mrn tul)e with wall coated silica) PLUS Control 2 5 (Plastic, 13xl00 mm tube with wall coated silica) CA 0223l7l4 l998-03-0~
TABLE. 5 (Part of Example 4) MEAN OF MEASURED ANALYTES
(SAMPLE SIZE, N=5 FOR EACH TUBE TYPE) Analyte Glass Plastic Prototype Control Control Sodium 139 138.8 ]39.6 (nlmol/l,) Potassium 4.02 4.02 4.06 (mmol/L) Chloride 100.4 100.6 100 (mmol/lJ) C(~2 27.2 27.6 27.8 (~lmol/L) LD 421.6 427.6 425.4 (IlJ/L) pE I 7.62 7.61 7.59 In Table 4, it is important to note that in all cases when fibrin was present in the prototype tubes, the size of the fibrin masses was markedly smaller than those presented by the corresponding control tubes. This was an indication of more complete clotting in the prototype tubes. In Table 5, the results from the analytes demonstrated medically significant differences compared with the control products. This demonstrates that the use of disintegrant material does not have an adverse impact on analyte values.
CA 02231714 1998-03-0~
PREPARATION OF ADDITIVE FORMULATION
The additive formulation of the present invention was prepared with the following ingredients as listed in Table 6:
Ingredients Weight Percent Ethylene(li~minetetraacetic acid dipotassium salt 50 (K2EDTA) (Anticoagulant) (Mfg.: SIGMA Chemicals, Lot #14H0457) Cil,ric Acid Monohydrate 16.33 (Mfg.: SIGMAC'hemicals, Lot#115H1018) Sodium bicarbonate 33.67 (Mfg.: SIGMA IChemicals, Lot #56H0423) In a mixlng vessel, all of the above ingredients were mixed together.
The mixture was then blended using a mortar and pestle for about 30 minutes or until a fine blend was obtained. Pellets weighing between about 7 to 8 mg each were formed using aL puncher. Because of the manual force applied on the puncher during the aliquoting process the powdered material formed into a pellet.
CA 02231714 1998-03-0~
CLINICAL EFFICACY OF THE ADDITIVE FORMULATION
c, To demonstrate the clinical efficacy of the additive, the pellets made according to Example 5 were evaluated for anticoagulant performance. Three 13 x 75 mm plastic evacuated tubes of 2ml draw each containing one pellet as made in Example 5 were used to collect blood from 3 human donors. The tubes were then evaluated for anticoagulant performance. The method for 10 evaluating anticoagulant performance was by visual inspection for gelation ofblood, as well as by observing microclots when the blood specimen is filtered through a fine meshed sieve. Any observation of visual clotting and/or the presence of microclots was deemed a failure. Table 7 shows the results from the clinical study.
1, Tube Type Handling Number of Condition Tubes that Passed Prototype no mixing 3 (formulation p~er Example-5 in 13x75 mm plastic evacuated tube, 2mL draw) Control #1 - no mixing (VACUTAINER brand tubes, cat # 367648, 2 mL, draw, K~EDTA sprayed on the tube wall) Control #2 - mixed by 3 (VACUTAINER brand tubes, cat #367648, 2 inverting tube mL draw, K~EDTA sprayed on the tube walV 10 times
as ellagic acid, -thrombin, trypsin and thromboplastin.
Typical clot activators used commercially are silica coated on fabric, silica particles in small plastic cups or silicate particles applied to the tubewall with a polyvinylpyrrolidone (PVP) carrier. However, in these type of arrangements, it is necessary for the user to initiate mixing of the sample so that the activator is bioavailabile to the specimen thus providing the desired effect of the aclditive in the sampLe. Therefore, the mixing requirement is critical to obtaining the desired effect of the additives.
Maximum effectiveness is ac:hieved by thorough dispersion of the clot activator throughout the blood sample. Since clot activator materials are generally in powder form or as a wall coating, mixing of the clot activator with the blood sample to achieve dispersion may be a physically awkward operation. Also complete dispersion of the clot activator material in the blood sample tends to be frustrated by the tendency of the clot activator material to agglomerate upon moistening.
In addition, agglomerated clot activator particles tend to settle relatively rapidly, according to Stokes Law, which provides that the settling rate of a particle in a dispensing fluid will be governed by its relative diameter and density as well as the fluid's viscosity and density.
Therefore, there is a need for providing a means for deploying an additive in a body fluid with minimal requirements of the user to initiate mixing of the additive and the body fluid and whereby the additive is able to provide rapid and reliable performance under variable handling conditions.
More particularly, there is a need for a blood collection tube with means for promoting c:lot-acceleration of a blood sample which provides an enhanced rate of blood coagulation (shortened time for blood coagulation) without leaving any substantial amount of soluble or particulate material in the serum layer on centrifugation, thus avoiding potential interference with CA 02231714 1998-03-0~
clinical tests, particularly in blood banking procedures. Whereas there are numerous commercial products available that employ clot activators, these products are unable to satisfactorily provide a shortened time for blood coagulation or provide a sample with minimal soluble or particulate material !, in the serum la'yer.
SUMMARY OF THE INVENTION
The present invention is an additive formulation for use in collection 10 devices wherein the additive preparation effervesces when in contact with a body fluid. The additive preparation desirably comprises a formulation comprising an aLdditive, an organic aLcid and a metal carbonate compound.
Desirably, the additive is a clot activator, anticoagulant, urine 1!~ preservation material or any other body fluid preservative.
In addition, the additive formulation may further comprise a stabilizer and/or a flow improver or a binder.
Desirably, the additive formulation comprises:
(a) from about 40 weight percent to about 90 weight percent of an additive;
(b) from about 5 weight percent to about 30 weight percent of an 2!~ organic acid or mixtures thereof; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate compound.
The present invention is most preferably an additive formulation for 30 enhancing clot activation of a b]Lood sample. The additive formulation CA 02231714 1998-03-0~
desirably comprises a clot activator, an organic acid and a metal carbonate compound.
Preferably, the clot activator additive formulation comprises:
, (a) from ;about 40 weight percent to' about 70 weight percent of a clot activa,tor;
(b) from about 10 weight percent; to about 26 weight percent of an organic acid or mixtures thereof; and o (c) from about 10 weight percent to about 26 weight percent of a metal carbonate.
The additive formulation ma,y further comprise a binding agent from about 6 weight percent to about 30 ~weight percent of a binder.
1 .~
The clot activator may be diatomaceous earth, particles of inorganic silicates or biochemicals such as ellagic acid, thrombin, trypsin and thromboplastin or combinations thereof.
21~ A significant attribute of t,he additive formulation of the present invention is its use in collection devices wherein the additive preparation effervesces when in contact with a body fluid sample. The effect of the additive preparation therefore aids in the dispersal and delivery of the additive to a body fluid sample.
A significant attribute of the clot activator additive formulation of the present invention is its use in blood collection devices as an effective and efficient means for promoting blood coagulation. Most importantly is that the additive formu],ation and the blood sample does not have to be mixed by the user.
CA 02231714 1998-03-0~
An import;ant advantage of the clot activator additive formulation of the present invention is its ease of use not requiring lengthy time to promote blood coagulation as compared to conventional techniques.
';
Notably, t,he formulations of t;he present invention rapidly disintegrate and disperse in a body fluid sample, thereby minimi7.ing the requirement that the user assist in mixing the formulation and the body flùid sample.
DESCRIPTION OF THE DRAWINGS
FIG. 1 is a perspective view of a typical blood collection tube with a stopper.
~, FIG. 2 is ;a longitudinal sectional view of the tube of FIG. 1 taken along line 2-2, comprising the additive formulation of the present invention.
DETAILED DESCRIPTION
The present invention may be embodied in other specific forms and is not limited to any specific embodim~ents described in detail which are merely exemplary. Various other modifical,ions will be apparent to and readily made by those skilled in the art without departing from the scope and spirit of the invention. The scope of the invention will be measured by the appended claims and their equivalents.
The addit,ive formulation of the present invention comprises:
(a) from about 40 weight percent to about 90 weight percent of a clot aCtiVcltOr;
(b) from about 5 weight percent to about 30 weight percent of an CA 02231714 1998-03-0~
organic acid; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate.
ci The additive formulation may further comprise a binding agent from about 5 weight percent to about 30 ~eight percent.
Desirably, the pH of the formulation is from about 5 to about 9, preferably from about 6 to about (3 and most preferably from about 6.5 to 10 about 7.5.
A clot activator material is preferably used in the formulation to initiate rapid c lotting of a blood sample that comes in contact with the formulation of the present invention.
1'~
A blood specimen often needs to be clotted to obtain serum. Serum is the specimen of choice for performing blood chemistries.
Desirably, the clot activator :materials, include, but are not limited to, 2l~ diatomaceous earth, inorganic silicates, ellagic acid, thrombin, trypsin and thromboplastin.
The preferred clot activator material for use in the formulation of the present invention is silica. A commercially available silica material is Min-U-Sil (trademark of Pennsylvania Glass Company, PA). Preferably, silica maybe present in the formulation such that the acceleration of the clotting mechanism is substantially achieved while minimi7.ing visual hemolysis or impacting chernistry analytes of the blood sample in an amount from about 40 to about 90 weight percent and most preferably at about 50 weight percent.
An organic acid is also preferably used in the formulation of the present CA 02231714 1998-03-0~
invention to initiate an effervescent reaction in the presence of water.
Desirably, the organic acid includes, but is not limited to, organic compounds containing at least one carboxylic acid functionality such as s tartaric acid, ci-tric acid, malic acid, maleic acid, fumaric acid, succinic acid, ascorbic acid and mixtures thereof.
The preferred organic acid for use in the formulation of the present invention is citric acid. Preferably, citric acid may be present in the o formulation in an amount from about 5 to about 30 weight percent and more preferably at about 25 weight percent.
A metal carbonate compound is also preferably used in the formulation of l;he present invention to initiate the disintegrating reaction in the presence 1!~ of acid and water.
Preferably, the metal carbonate compound is water soluble and includes, but is not limited to an alkali metal salt, sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate, cadmium carbonate, calcium carbonate, rubidium carbonate, potassium bicarbonate, soclium benzoate, sodium phosphate~ monobasic and sodium glycine carbonate.
Most pref-erably the metal carbonate compound is an alkali metal salt.
The preferred alkali metal salt for use in the formulation of the present invention is sodium bicarbonate. Preferably, sodium bicarbonate may be present in the formulation in an amount from about 5 to about 30 weight percent and more preferably at about 25 weight percent.
Most preferably the additive formulation of the present invention co m priSeS:
CA 02231714 1998-03-0~
(a) fronn about 50 weight percent of silica;
(b) fronn about 25 weight percent of citric acid; and (c) fronn about 25 weight percent of sodium bicarbonate.
';
An alternate embodiment of the present invention includes an additive formulation connprising:
(a) from aLbout 40 weight percent to about 90 weight percent of a clot activator;
(b) from about 5 weight percent to about 30 weight percent of an organic acid;
(c) from aLbout 5 weight percent to about 30 weight percent of a metal carbonate; and 1!~ (d) from about 5 weight percent to about 30 weight percent of a binding agent.
Most preferably the alternate embodiment of the present invention cornprlses:
21~
(a) frorn about 50 weight percent of a clot activator;
(b) frorn about 20 weight percent of an organic acid;
(c) from about 20 weight percent of a metal carbonate; and (d) from about 10 weight percent of a binder.
A binding or bulking agent may be used in the formulation of the present invention to provide binding and lubricating properties to the formulation.
Preferably the binding agent includes but is not limited to polyvinyl-py:rrolidone (PVP) polyvinyl-alcohol (PVA) polyethylene glycol (PEG) CA 02231714 1998-03-0~
carboxymethyl cellulose or corn starch.
The preferred binding agent for use in the formulation of the present invention is polyvinylpyrrolidone (E'VP). Preferably, PVP may be present in s the formulation in an amount from about 5 to about 30 weight percent.
A binding agent enables granulating of the formulation without the forming of a pellet.
o Polyvinylpyrrolidone is soluble in water and in a number of polar and non-polar organic solvents. Polyvinylpyrrolidone therefore serves as a binder and as a lubricant. Therefore, when the pellet of the present invention is dissolved in water, there is substantially no insoluble residue.
~, The polyvinylpyrrolidone used in the present invention is a polymer of vinylpyrrolidone having a molecular weight of about 1~,000 to about 200,000.
PVP is soluble in water and is also soluble in many organic solvents such as aliphatic alcohLols, chlorinated hydrocarbons, esters, nitroparaffins and am.lnes.
21~
Most prel-erably, the components of the formulation are in a physically bound form to maximize the dispersion of the formulation. They may be bound into pellets, pills, capsules, granules, tablets and the like may all be used in the practice of this invention. Most preferably, the formulation of the 2~ present invention is in pellet form. Pellet form is convenient because the formulation will rapidly disperse in the blood sample.
A dry compression techniqu.e may be used to form a pellet of the formulation of the present inventiom CA 0223l7l4 l998-03-0~ ' The dry oompression technique consists of mixing the components of the formulation and then applying sufficient force to form a pellet. The heat of compression binds the dry powder together, to form a pellet. The pellet formulation of l,he present invention is prepared by mixing the ingredients in a standard shaker for about two (2) hours or until a fine blend mixture is obt;ained. Then small portions of the mixed batch of powder are aliquoted into a manual puncher. The manual puncher consists of a piston-cylinder assembly. AlLiquoted powder is placed in the die cavity and force is applied by means of a hydraulic or pneumatic press. Typically, the aliquoting and pressing operal~ions are automatically performed in commercially available tablet presses.
Other ingredients which are conventional or desirable in various pellet formulations m.ay also be added to the formulation as long as they do not adversely affect; the overall properties of the formulation.
The addil,ive preparation of the present invention is preferably located in a collection clevice. The device is most preferably a blood collection deviceand may be eil,her an evacuated blood collection device or a non-evacuated blood collection device. The collection device is desirably made of plastic, such as but not limited to polyethylene terephthalate, or polypropylene or glass.
Referring to the drawings in which like reference characters refer to like parts throughout the several views thereof, FIG. 1 shows a typical blood collection device 10, having an open end 16, a closed end 18, inner wall 12, and a stopper 14 that includes a lower annular portion or skirt 15 which extends into and presses against the inner wall 12 of the tube for maintaining stopper 14 in p]Lace.
FIG. 2 shows device 10 with an additive preparation 20.
CA 0223l7l4 l998-03-0~
A blood specimen sample of interest can be transferred into device 10, wherein the specimen contacts the additive so that the additive rapidly disperses into t:he specimen and clot activation is initiated.
The following examples are not limited to any specific embodiment of the invention, blut are only exemplary.
PREPARATION OF ADDITIVE FORMULATION
The additive formulation of the present invention was prepared with the following ingredients as listed in Table 1:
Ingredients Weight Percent (%) Grams ~gm) silica 50 1.0 (Min-U-Sil, Pennsylvania Glass Compa:ny) baking soda 48 1.0 (Mixture of sodium bicarbonate and tartaric acid, Mfg: Arm and l~ammer) citric acid 2 0.0 (Sigma Chemicals Catalog No. C1909, Lot No.
~L~H0868) CA 0223l7l4 l998-03-0~
In a mixing vessel, all of the above ingredients were mixed together.
The mixture was then blended u sing a mortar and pestle for about 20 minutes or unt;il a fine blend was obtained. Twenty (20) pellets weighing !~ approximately 1.25 mg each were formed using a puncher. Because of the ma nual force applied on the puncher during the aliquoting process the powdered mate rial formed into a pellet.
1~
EFFECTI~IENESS EVAL,UATlON OF ADDITIVE FORMULATION
The effectiveness of the preparations of Example 1 were assessed by measuring the amount of silica available in the supernatant of added water.
1:5 In other words, the measurement oi-- silica not sedimented at the bottom of the tube whereby the silica in the su pernatant represents silica available for clotting in the blood.
The pellets prepared in Example 1 were added to twenty 16 x 100 mm plaLstic tubes. 'l'hese twenty tubes were separated into groups of ten, Group A
and Group B. Group C consisted of the control tubes~ twenty 13 x 100 mm plastic tubes with a wall coating c:onsisting of a mixture of silica, PVP and surfactant and a gel at the bottom. These tubes are VACUTAINER~' brand PL,US tubes.
The 16x100 mm tubes used in this experiment were marked for 8 ml fil~. There was also a second mark on these tubes, placed near the closed or bottom end of 1,he tube. The bottonn mark acted as an indicator for pipetting wa.ter from the tube, without disturbing the sedimented silica. This ensured that silica that is at the bottom oi- the tube is not aspirated along with the CA 02231714 1998-03-0~
supernatant, thus giving falsely elevated numbers for amount of silica in the solution.
These twenty tubes were further separated into groups of ten tubes each. The reason for the two separate groups was during the experiment one group was to be mixed while other one remained unmixed.
For controls, twenty 13xlO0 mm plastic tubes with wall coating consisting of a mixture of silica, PVP, and surfactant were used (VACUTAINE~'~ brand PLUS tubes, Lot # DG061096tI). These tubes also had gel at the bottom of the tube. These tubes were also separated into groups of 10 each.
De-ionized (DI) water was added to all the prototype and control tubes, one tube at a time. For the unmixed set of tubes, the DI water was immediately pipetted out. Nephelometry (Hach Turbiditimeter), which measures the amount of suspended particles, was done on these collected samples immediately. For the mixed tubes the methodology used was identical, except mixing with five inversions was done before pipetting the DI
water.
Table 2 llsts the amount of silica per mL of water in the supernatant.
The data clearly indicates that l;he pellets in both mixed and unmixed conditions outperformed the wall coated tubes.
SILICA IN SUPERNATANT
s (SAMPL]3 SIZE, N = 10) 'l'ube Type Handling Amt. of Silica Amt. of silica in (wt%) Condition dispensed the Supernatant (#of Inversions) (mg/mL) ~mg/mL) E'rototype 0 0.08 0.07 87.~
Control 0 0.15 0.05 33.33 Prototype ~ 0.08 0.1* 100 Control 6 0.15 0. 09 60 * Over recol)ery was attributed to the turbule~ce caused by m ixing and nephelometry reading the air bubbles irl mixing as silicaparticles.
11) PREPARATION OF ADDITIVE FORMULATION
, The addil,ive formulation of the present invention was prepared with the following ingredients as listed in Table 3:
TAlBLE 3 Imgredients Weight Percent s Llica 50 sodium bicarbonate 25 citric acid 25 CA 02231714 1998-03-0~
EXAMPI,E 4 CLINICAL EFFICACY OF THE PELLETS
r~ To demor-strate the clinical efficacy of the dispersion of the pellets in Example 3, a f:ive donor clinical study of human donors was performed and the clotting performance and select analytes of the samples were evaluated.
The measure of clotting performance was visual evaluation for gelation 10 of blood as well as presence of fibrin mass post centrifugation. The presence of fibrin mass after centrifugation demonstrates an incomplete clotting process even if the blood has completely gelled prior to centrifugation. In this experiment the prototype and control tubes were centrifuged for 10 minutes after waiting for 15 minutes post specimen collection 1~
Table 4 lists the visual observations done for clotting, while Table 5 lisl;s the results from the analyte measurements done on these tubes.
VISUAL OBSERVATIONS (SAMPLE SIZE N=5) Tube Type Number of Tubes not Fibrin Clotted before ~Iass Centrifugation Prototype 1 2 (Formulation per l~xamp]e 3)(13 X 100 mm plastic tube with first coat of surfactant, Pellet wt.=1.5 mg) Control- l 5 5 (Glass, 13xlOO mrn tul)e with wall coated silica) PLUS Control 2 5 (Plastic, 13xl00 mm tube with wall coated silica) CA 0223l7l4 l998-03-0~
TABLE. 5 (Part of Example 4) MEAN OF MEASURED ANALYTES
(SAMPLE SIZE, N=5 FOR EACH TUBE TYPE) Analyte Glass Plastic Prototype Control Control Sodium 139 138.8 ]39.6 (nlmol/l,) Potassium 4.02 4.02 4.06 (mmol/L) Chloride 100.4 100.6 100 (mmol/lJ) C(~2 27.2 27.6 27.8 (~lmol/L) LD 421.6 427.6 425.4 (IlJ/L) pE I 7.62 7.61 7.59 In Table 4, it is important to note that in all cases when fibrin was present in the prototype tubes, the size of the fibrin masses was markedly smaller than those presented by the corresponding control tubes. This was an indication of more complete clotting in the prototype tubes. In Table 5, the results from the analytes demonstrated medically significant differences compared with the control products. This demonstrates that the use of disintegrant material does not have an adverse impact on analyte values.
CA 02231714 1998-03-0~
PREPARATION OF ADDITIVE FORMULATION
The additive formulation of the present invention was prepared with the following ingredients as listed in Table 6:
Ingredients Weight Percent Ethylene(li~minetetraacetic acid dipotassium salt 50 (K2EDTA) (Anticoagulant) (Mfg.: SIGMA Chemicals, Lot #14H0457) Cil,ric Acid Monohydrate 16.33 (Mfg.: SIGMAC'hemicals, Lot#115H1018) Sodium bicarbonate 33.67 (Mfg.: SIGMA IChemicals, Lot #56H0423) In a mixlng vessel, all of the above ingredients were mixed together.
The mixture was then blended using a mortar and pestle for about 30 minutes or until a fine blend was obtained. Pellets weighing between about 7 to 8 mg each were formed using aL puncher. Because of the manual force applied on the puncher during the aliquoting process the powdered material formed into a pellet.
CA 02231714 1998-03-0~
CLINICAL EFFICACY OF THE ADDITIVE FORMULATION
c, To demonstrate the clinical efficacy of the additive, the pellets made according to Example 5 were evaluated for anticoagulant performance. Three 13 x 75 mm plastic evacuated tubes of 2ml draw each containing one pellet as made in Example 5 were used to collect blood from 3 human donors. The tubes were then evaluated for anticoagulant performance. The method for 10 evaluating anticoagulant performance was by visual inspection for gelation ofblood, as well as by observing microclots when the blood specimen is filtered through a fine meshed sieve. Any observation of visual clotting and/or the presence of microclots was deemed a failure. Table 7 shows the results from the clinical study.
1, Tube Type Handling Number of Condition Tubes that Passed Prototype no mixing 3 (formulation p~er Example-5 in 13x75 mm plastic evacuated tube, 2mL draw) Control #1 - no mixing (VACUTAINER brand tubes, cat # 367648, 2 mL, draw, K~EDTA sprayed on the tube wall) Control #2 - mixed by 3 (VACUTAINER brand tubes, cat #367648, 2 inverting tube mL draw, K~EDTA sprayed on the tube walV 10 times
Claims (33)
1. An additive preparation comprising an additive, an organic acid and a metal carbonate compound
2. The additive preparation of Claim 1 further comprising a binding agent.
3. The additive preparation of Claim 1 wherein said additive is clot activator, an anticoagulant or urine preservation material.
4. The additive preparation of Claim 1 wherein said organic acid is citric acid, tartaric acid, malic acid, maleic acid, fumaric acid, succinic acid or ascorbic acid, or mixtures thereof.
5. The additive preparation of Claim 1 wherein said metal carbonate compound is an alkali metal salt.
6. The additive preparation of Claim 5 wherein said alkali metal salt is sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate, cadmium carbonate, calcium carbonate, potassium bicarbonate, sodium benzoate, sodium phosphate monobasic or sodium glycine carbonate.
7. The additive preparation of Claim 6 wherein said alkali metal salt is sodium bicarbonate.
8. The additive preparation of Claim 2 wherein said binding agent is polyvinylpyrolidone, polyvinyl-alcohol, polyethylene glycol, carboxymethyl cellulose or corn starch.
9. An additive preparation comprising:
(a) from about 40 weight percent to about 90 weight percent of additive;
(b) from about 5 weight percent to about 30 weight percent of an organic acid or mixtures thereof; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate compound.
(a) from about 40 weight percent to about 90 weight percent of additive;
(b) from about 5 weight percent to about 30 weight percent of an organic acid or mixtures thereof; and (c) from about 5 weight percent to about 30 weight percent of a metal carbonate compound.
10. The additive preparation of Claim 9 further comprising about 5 weight percent to about 30 weight percent of a binding agent.
11. The additive preparation of Claim 9 wherein said additive is clot activator, an anticoagulant or urine preservation material.
12. The additive preparation of Claim 9 wherein said organic acid is citric acid, tartaric acid, malic acid, maleic acid, fumaric acid, succinic acid or ascorbic acid or mixtures thereof.
13. The additive preparation of Claim 9 wherein said metal carbonate compound is an alkali metal salt.
14. The additive preparation of Claim 13 wherein said alkali metal salt is sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate, cadmium carbonate, calcium carbonate, potassium bicarbonate, sodium benzoate, sodium phosphate monobasic or sodium glycine carbonate.
15. The additive preparation of Claim 14 wherein said alkali metal salt is sodium bicarbonate.
16. The additive preparation of Claim 10 wherein said binding agent is polyvinylpyrolidone, polyvinyl-alcohol, polyethylene glycol, carboxymethyl cellulose or corn starch.
17. An additive preparation comprising a clot activator, an organic acid and a metal carbonate compound.
18. The additive preparation of Claim 17, wherein said clot activator is selected from the group consisting of silica, diatomaceous earth, inorganic silicates, thrombin, ellagic acid, trypsin and thromboplastin and mixtures thereof.
19. The additive preparation of Claim 17, wherein said organic acid is selected from the group consisting of citric acid, tartaric acid, succinic acid and mixtures thereof.
20. The additive preparation of Claim 17, wherein said metal carbonate is selected from the group consisting of sodium bicarbonate, ammonium carbonate, sodium carbonate or rubidium carbonate.
21. An additive preparation comprising:
(a) about 50 weight percent to about 90 weight percent of clot activator;
(b) about 25 weight percent to about 30 weight percent of organic acid; and (c) about 25 weight percent to about 30 weight percent of metal carbonate.
(a) about 50 weight percent to about 90 weight percent of clot activator;
(b) about 25 weight percent to about 30 weight percent of organic acid; and (c) about 25 weight percent to about 30 weight percent of metal carbonate.
22. The additive preparation of Claim 21, wherein said clot activator is silica.
23. The additive preparation of Claim 21, wherein said organic acid is citric acid.
24. The additive preparation of Claim 21, wherein said metal carbonate is sodium bicarbonate.
25. A method for preparing a pellet additive formulation, comprising the steps of:
(a) mixing a clot activator or anticoagulant, citric acid and sodium bicarbonate in a shaker for about 2 hours or until a fine blend mixture is obtained;
(b) adding the mixture to the die cavity of a puncher;
(c) applying hydraulic or pneumatic pressure to the die cavity to form a pellet.
(a) mixing a clot activator or anticoagulant, citric acid and sodium bicarbonate in a shaker for about 2 hours or until a fine blend mixture is obtained;
(b) adding the mixture to the die cavity of a puncher;
(c) applying hydraulic or pneumatic pressure to the die cavity to form a pellet.
26. An assembly for collecting a body fluid, said assembly comprising:
(a) a container having an open end, a closed end and an inner and outer surface;
(b) an additive preparation contained within the container at the closed inner surface of the container.
(a) a container having an open end, a closed end and an inner and outer surface;
(b) an additive preparation contained within the container at the closed inner surface of the container.
27. A method for activating clotting of a blood sample, comprising the steps of:
(a) providing a container having an open end, a closed end, said container further having an additive preparation contained therein at the closed inner surface of the container;
(b) introducing said blood sample in said container with said additive preparation; and (c) mixing said sample in said container with the additive solution whereby the additive solution effervesces and mixes with said blood sample upon contact.
(a) providing a container having an open end, a closed end, said container further having an additive preparation contained therein at the closed inner surface of the container;
(b) introducing said blood sample in said container with said additive preparation; and (c) mixing said sample in said container with the additive solution whereby the additive solution effervesces and mixes with said blood sample upon contact.
28. An additive preparation comprising:
(a) silica;
(b) sodium bicarbonate;
(c) tartaric acid (d) citric acid
(a) silica;
(b) sodium bicarbonate;
(c) tartaric acid (d) citric acid
29. An additive preparation comprising:
(a) about 50 weight percent silica;
(b) about 48 weight percent sodium bicarbonate and tartaric acid;
and (c) about 2 weight percent citric acid.
(a) about 50 weight percent silica;
(b) about 48 weight percent sodium bicarbonate and tartaric acid;
and (c) about 2 weight percent citric acid.
30. An additive preparation comprising an anticoagulant, an organic acid and a metal carbonate compound.
31. The additive preparation of Claim 30, wherein said anticoagulant is ethylenediamineteraacetic acid dipotassium salt.
32. The additive preparation of Claim 30, wherein said metal carbonate is selected from the group consisting of sodium bicarbonate, ammonium carbonate, sodium carbonate or rubidium carbonate.
33. The additive preparation of Claim 30, wherein said organic acid is selected from the group consisting of citric acid, tartaric acid, succinic acid,and mixtures thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4515997P | 1997-04-30 | 1997-04-30 | |
US60/045,159 | 1997-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2231714A1 true CA2231714A1 (en) | 1998-10-30 |
Family
ID=21936316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002231714A Abandoned CA2231714A1 (en) | 1997-04-30 | 1998-03-05 | Additive preparation and method of use thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US6225123B1 (en) |
EP (1) | EP0875756B1 (en) |
JP (1) | JP3967456B2 (en) |
KR (1) | KR100473726B1 (en) |
CN (1) | CN1199609A (en) |
AU (1) | AU749445B2 (en) |
BR (1) | BR9801418A (en) |
CA (1) | CA2231714A1 (en) |
DE (1) | DE69821670T2 (en) |
ES (1) | ES2212166T3 (en) |
SG (1) | SG83678A1 (en) |
ZA (1) | ZA981866B (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534016B1 (en) | 1997-04-30 | 2003-03-18 | Richmond Cohen | Additive preparation and method of use thereof |
US5810775A (en) * | 1997-05-23 | 1998-09-22 | Shaw; Thomas J. | Cap operated retractable medical device |
US6979307B2 (en) * | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US7745106B2 (en) * | 1997-06-24 | 2010-06-29 | Cascade Medical Enterprises, Llc | Methods and devices for separating liquid components |
US7947236B2 (en) | 1999-12-03 | 2011-05-24 | Becton, Dickinson And Company | Device for separating components of a fluid sample |
JP2001321368A (en) * | 2000-05-16 | 2001-11-20 | Fuji Photo Film Co Ltd | Plasma taking tool |
US6629958B1 (en) | 2000-06-07 | 2003-10-07 | Ronald P. Spinello | Leak sealing needle |
CA2420149C (en) * | 2000-08-24 | 2006-10-31 | Bio-Rad Laboratories, Inc. | Dry powder formulation for protein labeling |
CA2450639C (en) * | 2001-06-18 | 2012-03-20 | Becton, Dickinson And Company | Multilayer containers and process for forming multilayer containers |
BR0309976A (en) * | 2002-05-13 | 2005-03-01 | Becton Dickinson Co | Protease Inhibitor Sample Collection System |
JP2006502415A (en) * | 2002-10-10 | 2006-01-19 | ベクトン・ディキンソン・アンド・カンパニー | Sample collection system with caspase inhibitor |
US20050124965A1 (en) * | 2003-12-08 | 2005-06-09 | Becton, Dickinson And Company | Phosphatase inhibitor sample collection system |
WO2006057225A1 (en) * | 2004-11-25 | 2006-06-01 | Matsushita Electric Industrial Co., Ltd. | Sensor device |
US7396342B2 (en) * | 2005-11-25 | 2008-07-08 | Biotop Holding Co., Ltd. | Safety syringe for taking blood |
US20070123822A1 (en) * | 2005-11-25 | 2007-05-31 | Biotop Holding Co., Ltd. | Safety syringe for taking blood |
US20080009806A1 (en) * | 2006-07-10 | 2008-01-10 | Biotop Holding Co., Ltd. | Blood sampling device |
US9259174B2 (en) * | 2007-04-20 | 2016-02-16 | Stat Medical Devices, Inc. | Retractable fluid collection device |
WO2008132462A1 (en) * | 2007-04-27 | 2008-11-06 | Safeguard Biosystems Holdings Limited | Sampling device |
ES2553089T3 (en) * | 2007-11-27 | 2015-12-04 | La Seda De Barcelona S.A. | Transparent multilayer injection molded container having a fluoropolymer barrier layer |
WO2009140529A2 (en) * | 2008-05-14 | 2009-11-19 | John Stephens | Needle protective device |
ES2545462T3 (en) | 2008-07-21 | 2015-09-11 | Becton Dickinson And Company | Density phase separation device |
AU2009274096B2 (en) | 2008-07-21 | 2012-08-02 | Becton, Dickinson And Company | Density phase separation device |
CN102149472B (en) | 2008-07-21 | 2014-08-13 | 贝克顿·迪金森公司 | Density phase separation device |
US20100256524A1 (en) | 2009-03-02 | 2010-10-07 | Seventh Sense Biosystems, Inc. | Techniques and devices associated with blood sampling |
US8167820B2 (en) * | 2009-03-20 | 2012-05-01 | Mahurkar Sakharam D | Retractable needle-safety blood sampling device |
US20100286558A1 (en) * | 2009-04-08 | 2010-11-11 | Stat Medical Devices, Inc. | Fluid collection/injection device having quick release/removable double-ended needle and safety system |
CA2949850C (en) | 2009-05-15 | 2018-03-13 | Becton, Dickinson And Company | Density phase separation device |
CN102596034A (en) * | 2009-09-04 | 2012-07-18 | 阿托莫诊断私人有限公司 | Sample collecting device |
EP2490751B1 (en) | 2009-10-23 | 2016-11-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
WO2011091013A1 (en) | 2010-01-19 | 2011-07-28 | Becton, Dickinson And Company | Container assembly and system for detection thereof |
US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
WO2012064802A1 (en) * | 2010-11-09 | 2012-05-18 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
US10092230B2 (en) | 2011-04-29 | 2018-10-09 | Stat Medical Devices, Inc. | Fluid collection/injection device having safety needle assembly/cover and safety system and method |
EP2701598A1 (en) | 2011-04-29 | 2014-03-05 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
EP2702406B1 (en) | 2011-04-29 | 2017-06-21 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
KR102237667B1 (en) | 2011-04-29 | 2021-04-12 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
US9078978B2 (en) | 2011-12-28 | 2015-07-14 | Stat Medical Devices, Inc. | Needle assembly with safety system for a syringe or fluid sampling device and method of making and using the same |
US20160219870A1 (en) * | 2013-09-17 | 2016-08-04 | Becton, Dickinson And Company | Stabilization of Blood pH During Sample Storage |
WO2015089626A1 (en) | 2013-12-16 | 2015-06-25 | The University Of British Columbia | Self-fueled particles for propulsion through flowing aqueous fluids |
CN204050005U (en) * | 2014-09-09 | 2014-12-31 | 赵潺 | Disposable negative pressure paracentesis needle |
SG11201606297UA (en) * | 2014-10-14 | 2016-08-30 | Becton Dickinson Co | Blood sample management using open cell foam |
BR112017007534B1 (en) | 2014-10-14 | 2022-09-27 | Becton, Dickinson And Company | SPECIMEN TRANSFER DEVICE, SPECIMEN TRANSFER AND TESTING SYSTEM COMPRISING SUCH SPECIMEN TRANSFER AND LANCET DEVICE AND DEVICE |
US9694359B2 (en) | 2014-11-13 | 2017-07-04 | Becton, Dickinson And Company | Mechanical separator for a biological fluid |
CN110100814A (en) * | 2019-06-19 | 2019-08-09 | 佛山市安伦医疗器械有限公司 | A kind of whole day urine preservative, preparation method and applications |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB708996A (en) * | 1954-04-15 | 1954-05-12 | Miles Lab | Improvements in or relating to diagnostic compositions |
US3105792A (en) | 1960-11-29 | 1963-10-01 | Warner Lambert Pharmaceutical | Stable effervescent compositions and method of preparing same |
US3136692A (en) | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
FR1486M (en) * | 1961-08-30 | 1962-09-17 | Marcelle Martha | New anti-coagulant drug. |
US3852194A (en) | 1972-12-11 | 1974-12-03 | Corning Glass Works | Apparatus and method for fluid collection and partitioning |
US3962107A (en) | 1974-06-24 | 1976-06-08 | Johnson & Johnson | Enzyme-containing denture cleanser tablet |
US4079729A (en) * | 1975-10-31 | 1978-03-21 | Sherwood Medical Industries Inc. | Fluid collection with vacuum loss indicating means |
US4093710A (en) | 1976-07-07 | 1978-06-06 | Sandoz, Inc. | Rapid dissolving effervescent granules |
US4153739A (en) | 1977-06-30 | 1979-05-08 | Becton, Dickinson And Company | Method for collecting blood |
US4267164A (en) * | 1980-01-31 | 1981-05-12 | Block Drug Company Inc. | Effervescent stannous fluoride tablet |
US4344929A (en) | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
JPS57106622A (en) * | 1980-12-24 | 1982-07-02 | Toray Silicone Co Ltd | Coagulation accelerator of blood |
US4451454A (en) * | 1981-06-16 | 1984-05-29 | Wong Dennis W | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals |
US4956300A (en) * | 1982-01-05 | 1990-09-11 | Helena Laboratories Corporation | Aid for determining the presence of occult blood, method of making the aid, and method of using the aid |
JPS609009B2 (en) | 1982-10-15 | 1985-03-07 | 花王株式会社 | Foaming bath agent |
US4579828A (en) | 1983-12-15 | 1986-04-01 | Becton, Dickinson And Company | Clot activator for serum separation tubes |
JPS60215620A (en) | 1984-04-12 | 1985-10-29 | Kao Corp | Weak-acidity bath preparation |
US4827944A (en) | 1987-07-22 | 1989-05-09 | Becton, Dickinson And Company | Body fluid sample collection tube composite |
JPH01165527A (en) * | 1987-12-23 | 1989-06-29 | Tsumura & Co | Preparation of extract of chinese medicine |
CA1329134C (en) | 1988-03-17 | 1994-05-03 | Yuji Ichii | Bathing preparation |
CA2009118C (en) | 1989-02-21 | 1996-02-27 | Mary F. Mowrey-Mckee | Method and composition for cleaning and disinfecting contact lenses |
EP0391851B1 (en) * | 1989-04-07 | 1994-06-22 | Ciba-Geigy Ag | Concentrates of pesticidal active agents and their preparation |
US5297561A (en) | 1989-06-15 | 1994-03-29 | Hulon Walter C | Blood collection tube assembly |
US5110603A (en) | 1991-01-31 | 1992-05-05 | Kao Corporation | Bathing preparation for colloidal material |
US5114647A (en) | 1991-02-01 | 1992-05-19 | Olin Corporation | Effervescent tablets having increased disintegration rates |
CA2067691C (en) | 1991-05-13 | 1995-12-12 | James A. Burns | Stopper-shield combination closure |
JP3031647B2 (en) | 1992-02-08 | 2000-04-10 | 日立粉末冶金株式会社 | Extruder for powder material |
US5246666A (en) * | 1992-05-08 | 1993-09-21 | Becton, Dickinson And Company | Additive having dual surface chemistry for blood collection container and assembly containing same |
JPH0771642A (en) | 1992-11-06 | 1995-03-17 | Nachi Fujikoshi Corp | Three-way fluid control valve with check valve |
FR2698788B1 (en) | 1992-12-09 | 1995-03-03 | Union Pharma Scient Appl | Effervescent pharmaceutical composition containing ibuprofen and process for its preparation. |
ATE140621T1 (en) | 1993-04-15 | 1996-08-15 | Gergely Gerhard | SHOWER SYSTEM WITH AN ALKALINE AND/OR METAL SENSITIVE PHARMACEUTICAL ACTIVE INGREDIENT, AND METHOD FOR PRODUCTION |
US5326535A (en) * | 1993-04-30 | 1994-07-05 | Becton, Dickinson And Company | Tube having unitary blood coagulation activator and method for its preparation |
US5378431A (en) * | 1993-06-14 | 1995-01-03 | Becton, Dickinson And Company | Dual pathway clotting enhancer for blood collection tube |
JP3075037B2 (en) | 1993-09-06 | 2000-08-07 | 松下電器産業株式会社 | Shut-off valve |
US5455009A (en) * | 1993-09-14 | 1995-10-03 | Becton, Dickinson And Company | Blood collection assembly including clot-accelerating plastic insert |
JPH0789157A (en) | 1993-09-24 | 1995-04-04 | Canon Inc | Recording device and information processing system with the device |
US5320812A (en) * | 1993-10-04 | 1994-06-14 | Becton, Dickinson And Company | Clot activating polyelectrolyte complex and blood collection assembly containing same |
US5384062A (en) * | 1993-12-01 | 1995-01-24 | Warner-Lambert Company | Perborate persulfate: protease denture cleanser tablet composition |
US5494817A (en) * | 1993-12-06 | 1996-02-27 | Allergan, Inc. | Sugar-based protease composition for use with constant-PH borate buffers |
US5423758A (en) * | 1993-12-16 | 1995-06-13 | Shaw; Thomas J. | Retractable fluid collection device |
US5556643A (en) * | 1993-12-22 | 1996-09-17 | Hydrite Chemical Co. | Anticoagulant compositions |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
AT403041B (en) * | 1994-02-25 | 1997-10-27 | Zimmermann Horst | TELESCOPIC STICK |
EP0670160B1 (en) | 1994-03-01 | 1999-07-14 | Gerhard Dr. Gergely | Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation |
US5593639A (en) | 1994-05-26 | 1997-01-14 | Japan Synthetic Rubber Co., Ltd. | Blood-sampling vessel |
US5511558A (en) * | 1994-06-06 | 1996-04-30 | Becton, Dickinson And Company | Blood collection assembly having additive dispensing means and method for sample collection using same |
CA2168935C (en) * | 1995-02-21 | 2000-06-27 | Nicholas A. Grippi | Blood collection assembly having additive dispensing means and method for sample collection using same |
US5634474A (en) * | 1995-04-28 | 1997-06-03 | Becton, Dickinson And Company | Blood collection assembly including clot-accelerating glass insert |
US5567389A (en) | 1995-07-07 | 1996-10-22 | United Technologies Corporation | Method for controlled dispensing of extended-release chemical formulation in tablet form |
ES2151939T3 (en) * | 1995-07-21 | 2001-01-16 | Becton Dickinson Co | METHOD AND APPLIANCE TO DETERMINE THE RATE OF SEDIMENTATION OF Erythrocytes. |
-
1997
- 1997-08-14 US US08/911,394 patent/US6225123B1/en not_active Expired - Lifetime
-
1998
- 1998-03-05 CA CA002231714A patent/CA2231714A1/en not_active Abandoned
- 1998-03-05 ZA ZA981866A patent/ZA981866B/en unknown
- 1998-04-09 SG SG9800828A patent/SG83678A1/en unknown
- 1998-04-14 AU AU60795/98A patent/AU749445B2/en not_active Expired
- 1998-04-20 BR BR9801418A patent/BR9801418A/en not_active IP Right Cessation
- 1998-04-21 EP EP98107186A patent/EP0875756B1/en not_active Expired - Lifetime
- 1998-04-21 ES ES98107186T patent/ES2212166T3/en not_active Expired - Lifetime
- 1998-04-21 DE DE69821670T patent/DE69821670T2/en not_active Expired - Lifetime
- 1998-04-28 CN CN98108023A patent/CN1199609A/en active Pending
- 1998-04-28 KR KR10-1998-0015061A patent/KR100473726B1/en not_active IP Right Cessation
- 1998-04-30 JP JP12137998A patent/JP3967456B2/en not_active Expired - Lifetime
- 1998-09-30 US US09/164,539 patent/US6024710A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP3967456B2 (en) | 2007-08-29 |
EP0875756A3 (en) | 2000-03-29 |
JPH10323341A (en) | 1998-12-08 |
KR100473726B1 (en) | 2005-07-18 |
AU749445B2 (en) | 2002-06-27 |
US6024710A (en) | 2000-02-15 |
AU6079598A (en) | 1998-11-05 |
DE69821670T2 (en) | 2004-10-07 |
DE69821670D1 (en) | 2004-03-25 |
BR9801418A (en) | 1999-05-04 |
SG83678A1 (en) | 2001-10-16 |
EP0875756B1 (en) | 2004-02-18 |
EP0875756A2 (en) | 1998-11-04 |
US6225123B1 (en) | 2001-05-01 |
ZA981866B (en) | 1998-09-09 |
ES2212166T3 (en) | 2004-07-16 |
CN1199609A (en) | 1998-11-25 |
KR19980081787A (en) | 1998-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0875756B1 (en) | Additive preparation and method of use thereof | |
EP1215494B1 (en) | Method of preparing a blood collection device and an additive composition | |
US5830410A (en) | Oral collection device and kit | |
US6083760A (en) | Sol capture immunoassay kit and procedure | |
US4786471A (en) | Heterogeneous immunoassay method and assembly | |
JPH05188053A (en) | Instrument for separating serum or plasma component from blood | |
US20020015663A1 (en) | Oral collection device and kit | |
JP2012137493A (en) | Specimen collecting, processing and analytical assembly | |
US7498028B2 (en) | Preparation of spheres for diagnostic tests | |
JP2007511768A (en) | Fluid sample analyzer with sealable sample storage reservoir | |
EP2320208B1 (en) | Blood collection container | |
AU2021200665A1 (en) | Device and method for collecting and detecting samples | |
JP2750283B2 (en) | Apparatus for inhibiting glycolysis in blood samples | |
AU2002300487B2 (en) | Additive preparation and method of use thereof | |
MXPA98001994A (en) | Additive preparation and method of use of the mi | |
JP3495106B2 (en) | Blood component adhesion preventing agent, blood test container and blood component adhesion preventing carrier | |
AU687567B2 (en) | Apparatus for inhibiting glycolysis in blood samples | |
EP0354799A1 (en) | Method and means for allergy diagnosis | |
JP2001108670A (en) | Stool collecting container for determining stool occult blood and method for determining stool occult blood | |
JPH08292190A (en) | Blood examination container |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |